Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders GlobeNewswire December 31, 2025 TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)–a differentiated, dual PARP and WNT pathway inhibitor–today issued the following letter to shareholders […]